Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIAI study of anti-infliximab and anti-adalimumab immunization in rheumatoid arthritis
NL-OMON42704Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab and adalimumab in rheumatoid arthritis (RA) (2 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: Antibodies against biologicals after 3 months. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
infliximabadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON42704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42704.